This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
CLL Society was lucky when Elizabeth Cohen, MPH, CNN’s Senior Medical Correspondent, reached out to learn more about the needs of the immunocompromised for the article she was writing. I was able to suggest some contacts and help frame the discussion.
It’s a good article that touches on themes familiar to many of our readers and offers voice to those with chronic lymphocytic leukemia/small lymphocytic lymphoma and other immune compromising conditions.
Here is the CNN article: There’s a new drug to prevent COVID-19, but there won’t be nearly enough for Americans who are eligible.
Thank you to Elizabeth and all the patients and professionals that contributed to the article. We need to get the word out.
While she focused on EVUSHELD, the recently authorized, long-acting monoclonal antibody combination for pre-exposure prophylaxis (PrEP) that appears to retain its activity against Omicron, we face the same supply issues with sotrovimab and the new antivirals (as I explained in my recent UPDATE that also offers some coping strategies for living with uncertainty).
Heck, we can’t even get enough COVID-19 tests two years into the pandemic. Didn’t anyone see that coming?
CLL Society is working in front of the cameras and behind the scenes to improve our lot. Thank you for your support and confidence.
Please consider supporting our advocacy and our support, education, and research efforts through a DONATION to the CLL Society.
Together, we are making a positive difference.
Stay strong. We are all in this together.
Brian Koffman, MDCM (retired), MS Ed (he, him, his)
Co-Founder, Executive VP and Chief Medical Officer
CLL Society, Inc.